Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NOLA (NeuWave Observational Liver Ablation) Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04107766
Recruitment Status : Recruiting
First Posted : September 27, 2019
Last Update Posted : February 10, 2021
Sponsor:
Information provided by (Responsible Party):
Ethicon, Inc.

Brief Summary:
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.

Condition or disease Intervention/treatment
Cancer of the Liver Liver Cancer Neoplasms, Liver Device: Microwave Ablation

Detailed Description:

This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System. The data gathered from participating sites will be available to be analyzed to develop ablation parameter guidance for ablation approaches under varying patient liver tissue conditions and liver lesions.

This is an "umbrella registry," which was included as an optional component in other NEUWAVE studies; hence, data from consenting patients who are or will be enrolled in other NEUWAVE soft tissue liver lesion ablation studies will be included in this registry. All other patients will be enrolled and followed prospectively, enrolled retrospectively with prospective, longitudinal follow up, or enrolled retrospectively with all retrospective follow up.

Enrollment for this study will include at least 1,500 patients throughout the world who underwent or are undergoing microwave ablation of one or more soft tissue liver lesions using the NEUWAVE Microwave Ablation System or the NEUWAVE Microwave Ablation System with Ablation Confirmation.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Case-Only
Time Perspective: Other
Official Title: A Multicenter Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue Lesions
Actual Study Start Date : January 15, 2020
Estimated Primary Completion Date : December 31, 2026
Estimated Study Completion Date : December 31, 2026

Group/Cohort Intervention/treatment
Population
Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.
Device: Microwave Ablation
Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.




Primary Outcome Measures :
  1. Technical success [ Time Frame: Day of ablation (Day 0) ]
    Technical success, defined as ablation of the target lesion(s) according to the protocol and covered completely, with an adequate margin, as defined by the performing physician (i.e. the ablation zone completely overlaps or encompasses the target lesion(s) plus an ablative margin), as assessed by CT, MRI, PET, US, and/or X-ray, immediately following the procedure.

  2. Technical efficacy [ Time Frame: 7 days to 3 months post-ablation ]
    Technique efficacy, ablation of the target lesion(s) according to the protocol and covered completely, with an adequate margin, as defined by the performing physician (i.e., the ablation zone completely overlaps or encompasses the target lesion(s) plus an ablative margin), as assessed by CT, MRI, PET, US, and/or X-ray, at Visit 3 (between 7 days and less than 3 months post-ablation).

  3. Target lesion recurrence (local recurrence) rate [ Time Frame: 5 years post-ablation ]
    Target lesion recurrence (local recurrence) rate is evaluated at every visit after ablation of the target lesion(s), and overall evaluation at the 5-year follow-up, as assessed by CT, MRI, PET, US, and/or X-ray.


Secondary Outcome Measures :
  1. Secondary efficacy rate [ Time Frame: 5 years post-ablation ]
    Secondary efficacy rate, defined as the percentage of soft tissue lesions that have undergone successful repeat ablations (target or non-target) following identification of local soft tissue lesion progression, as assessed by CT, MRI, PET, US, and/or X-ray. A successful repeat ablation will be defined as ablation of the lesion according to the protocol and covered completely, with an adequate margin, as defined by the performing physician (i.e. the ablation zone completely overlaps or encompasses the lesion plus an ablative margin), as assessed by CT, MRI, PET, US, and/or X-ray, immediately following the procedure.

  2. Recurrence rate at a distant location (outside the initial treatment site(s)) [ Time Frame: 5 years post-ablation ]
    Recurrence rate at a distant location (outside the initial treatment site(s)), evaluated at every visit after ablation of the target lesion(s), and overall evaluation at the 5-year follow-up, as assessed by CT, MRI, PET, US, and/or X-ray.

  3. Recurrence-free survival [ Time Frame: 5 years post-ablation ]
    Recurrence-free survival, evaluated at every visit after ablation of the target lesion(s), and overall evaluation at the 5-year follow-up, as assessed by CT, MRI, PET, US, and/or X-ray.

  4. Overall survival [ Time Frame: 5 years post-ablation ]
    Overall survival, evaluated at every visit after ablation of the target lesion(s), and overall evaluation at the 5-year follow-up.

  5. Economic impact of ablation as evaluated by complete procedure duration [ Time Frame: Day of ablation (Day 0) through hospital discharge, estimated up to 1 week ]
  6. Economic impact of ablation as evaluated by complete ablation duration [ Time Frame: Day of ablation (Day 0) through hospital discharge, estimated up to 1 week ]
  7. Economic impact of ablation as evaluated by number of ablations [ Time Frame: Day of ablation (Day 0) through hospital discharge, estimated up to 1 week ]
  8. Economic impact of ablation as evaluated by length of hospital stay [ Time Frame: Day of ablation (Day 0) through hospital discharge, estimated up to 1 week ]
  9. Economic impact of ablation as evaluated by number of probes used [ Time Frame: Day of ablation (Day 0) through hospital discharge, estimated up to 1 week ]
  10. Economic impact of ablation as evaluated by types of probes used [ Time Frame: Day of ablation (Day 0) through hospital discharge, estimated up to 1 week ]
  11. Incidence of reportable Adverse Events/Serious Adverse Events (AEs/SAEs) [ Time Frame: 5 years post-ablation ]
    Incidence of adverse events (AEs) (SAEs) that are deemed at least unlikely related to the procedure or device and all serious adverse events (SAEs) from day of ablation through the end of the study.

  12. Quality of Life Questionnaires (QLQ-C30 and QLQ-HCC18) [ Time Frame: 9-12 months post-ablation ]

    European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and liver-specific QLQ-HCC18 are questionnaires that will be completed at each study visit up to 9-12 months post-ablation.

    Note: These two questionnaires were chosen as tools to assess overall health status/quality of life in the patient population with soft-tissue liver lesions.


  13. Numeric Pain Rating Scale [ Time Frame: 7 days to 3 months post-ablation ]
    The Numeric Pain Rating Scale is a questionnaire where the patient reports their pain utilizing a 0-10 scale (where 0 is 'no pain' and 10 is 'maximum pain'). Patients will complete this questionnaire at every study visit through 7 days to 3 months post-ablation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with at least one soft-tissue liver lesion ablated with the NEUWAVE Microwave Ablation System or NEUWAVE Microwave Ablation System with Ablation Confirmation.
Criteria

Inclusion Criteria:

  1. Patients who underwent or are scheduled to undergo a microwave ablation of one or more liver lesions with the NEUWAVE Microwave Ablation System per the device's Instructions for Use (IFU).
  2. Patients with signed informed consent (or waiver approved by IRB/EC) who are willing to comply with the assessment schedule, and willing to have data included in the database.
  3. Patients greater than or equal to 22 years old at the time of informed consent (or waiver approved by IRB/EC).

Exclusion Criteria:

1) Patients with a life expectancy of less than 1 year, in the opinion of the treating physician.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04107766


Contacts
Layout table for location contacts
Contact: Jaclyn Calia 908-218-2933 jcalia@its.jnj.com
Contact: Julie Peveto 908-218-3659 jpeveto@its.jnj.com

Locations
Layout table for location information
United States, California
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92354
Principal Investigator: Roger Tomihama, MD         
UCLA Recruiting
Los Angeles, California, United States, 90095
Principal Investigator: Justin McWilliams, MD         
Sutter Institute for Medical Research Recruiting
Sacramento, California, United States, 95816
Principal Investigator: Christopher Laing, MD         
Olive View UCLA Recruiting
Sylmar, California, United States, 91342
Principal Investigator: Thomas Le, MD         
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Principal Investigator: Beau Toskich, MD         
Sarasota Memorial Hospital Recruiting
Sarasota, Florida, United States, 34239
Principal Investigator: Scott Perrin, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Principal Investigator: Colette Shaw, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Bruno Odisio, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Principal Investigator: Ziv Haskal, MD         
France
Hôpital Européen Georges-Pompidou Recruiting
Paris, France, 75015
Principal Investigator: Olivier Pellerin, MD. PhD.         
Netherlands
University Medical Center Goningen Recruiting
Groningen, Netherlands, 9713 GZ
Principal Investigator: Koert de Jong, MD         
Sponsors and Collaborators
Ethicon, Inc.
Layout table for additonal information
Responsible Party: Ethicon, Inc.
ClinicalTrials.gov Identifier: NCT04107766    
Other Study ID Numbers: NEU_2017_04
First Posted: September 27, 2019    Key Record Dates
Last Update Posted: February 10, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
URL: http://yoda.yale.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases